Vaccinul BCG şi infecţia cu SARS-CoV-2

Until the development of a specific vaccine, the COVID-19 pandemic, determined by the new type of coronavirus, SARS-CoV-2, requires therapeutic interventions capable of influencing the morbidity and mortality in healthy and infected individuals. In this context, it has been hypothesized that a number of vaccines, including Bacillus Calmette-Guerin vaccine, can influence the immune system for the protection of people and the evolution of SARS-CoV-2 infection in a milder form. The pros and cons of the BCG vaccine need to be demonstrated or refuted in randomized clinical trials initiated in different countries and geographical regions with initial, intermediate or final outcomes, including countries with different immunization policies.